


PHARMACEUTICAL 2022



Bolt Biotherapeutics Inc. Rank 207 of 475





PHARMACEUTICAL 2022



Bolt Biotherapeutics Inc. Rank 207 of 475

The relative strengths and weaknesses of Bolt Biotherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bolt Biotherapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Bolt Biotherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is -69%, being 208% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	189,160
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,328
Liabilities, Non-Current	22,064
Other Assets	112,400
Other Compr. Net Income	-321
Other Expenses	0
Other Liabilities	14,207
Other Net Income	-5,803
Property and Equipment	6,158
Research and Development	75,655
Revenues	1,260
Selling, General and Administrative Expense	18,393

Output Variable	Value in 1000 USD
Assets	307,718
Liabilities	57,599
Expenses	94,048
Stockholders Equity	250,119
Net Income	-98,591
Comprehensive Net Income	-98,752
Economic Capital Ratio	-69%